HIGHLIGHTS
- who: Roald van der Laan from the to treat refractory NTM-PD caused by Mycobacterium avium complex (MAC) and is approved in the US, EU have published the article: Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery, in the Journal: (JOURNAL)
- what: The aim of this narrative review is to outline many of these factors and their implications for the treatment of NTM-PD, specifically focusing on challenges from the perspective of the NTM organism and disease process, and to discuss . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.